Saturday 17 October 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
17.57
0.58
−3.20%
Follow PRCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.82 | 4.39 | 5.67 | 6.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(66.94) | (37.07) | (169.21) | (299.76) | |
P/B ratio |
3.79 | 4.07 | 4.78 | 5.23 | |
Price to Tangible BV |
3.80 | 4.07 | 4.79 | 5.24 | |
EV/Sales |
3.30 | 3.79 | 4.92 | 5.83 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.99) | (17.42) | (30.92) | (24.61) | |
EV/FCF |
(13.12) | (15.16) | (25.96) | (21.93) | |
Quick Ratio |
5.23 | 5.37 | 5.62 | 7.03 | |
Current Ratio |
6.55 | 6.73 | 6.85 | 8.44 | |
Net Debt/EBITDA |
6.94 | 6.28 | 8.01 | 11.25 | |
Debt/Assets |
10.79% | 10.61% | 10.16% | 10.08% | |
Debt/Equity |
0.15 | 0.15 | 0.14 | 0.14 | |
Asset Turnover |
0.68 | 0.64 | 0.59 | 0.68 | |
Operating CF/Net income |
0.72 | 1.21 | 0.35 | 0.31 | |
Capex/Depreciation |
(1.48) | (1.68) | (1.08) | (1.77) | |
Interest Coverage |
(32.53) | (39.86) | (34.68) | (25.24) | |
Research and Development Expense of Revenue |
21.27% | 25.82% | 24.95% | 21.83% | |
Selling, General and Administrative Expense of Revenue |
73.72% | 78.29% | 76.32% | 70.82% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.38% | 15.72% | 14.19% | 17.39% | |
Graham Net Nets |
0.22 | 0.20 | 0.18 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.59%) | (7.28%) | (5.44%) | (4.29%) | |
Free Cash Flow Yield |
(6.59%) | (5.70%) | (3.34%) | (4.01%) | |
Revenue per Share |
1.66 | 1.47 | 1.38 | 1.50 | |
Operating CF per Share |
(0.34) | (0.67) | (0.19) | (0.12) | |
Capex per Share |
(0.05) | (0.05) | (0.03) | (0.05) | |
Free Cash Flow per Share |
(0.39) | (0.73) | (0.22) | (0.17) | |
Cash per Share |
3.99 | 4.35 | 5.16 | 5.28 | |
Shareholders Equity per Share |
5.96 | 6.15 | 6.59 | 6.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.96 | 6.15 | 6.59 | 6.82 | |
Free Cash Flow |
(22.20) | (41.04) | (12.18) | (9.50) | |
Working Capital |
356.09 | 364.40 | 384.58 | 400.85 | |
Capital Expenditures |
(2.95) | (2.91) | (1.85) | (2.87) | |
Net Current Asset Value |
281.00 | 288.64 | 308.17 | 323.49 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.04 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
94.21 | 87.83 | 83.51 | 76.78 | |
Average Payables |
13.43 | 16.84 | 13.66 | 13.10 | |
Average Inventory |
72.05 | 69.93 | 63.43 | 58.78 | |
Average Assets |
496.20 | 503.22 | 521.05 | 442.84 | |
Average Common Equity |
362.93 | 368.41 | 384.05 | 310.75 |
Columns are period end dates